Original Research
Published on 09 Sep 2025
Soluble B-cell maturation antigen as a serum marker of MRD in patients with multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1631511
- 1,996 views
37 articles related to "B Cell Maturation Antigen"
Articles
Case Report
Published on 18 Sep 2025
Case Report: Safety and efficacy assessment of teclistamab in relapsed/refractory amyloidosis: a case study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1664171
- 2,109 views
Case Report
Published on 05 Jan 2026
Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1705843
- 1,400 views
Case Report
Published on 29 Nov 2024
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1495233
- 4,895 views
- 5 citations
Review
Published on 01 Aug 2025
Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2025.1523392
- 6,621 views
- 2 citations
Review
Published on 28 Jul 2020
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2020.01243
- 35,471 views
- 81 citations
Mini Review
Published on 05 Aug 2020
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2020.01362
- 24,613 views
- 83 citations
Review
Published on 24 Nov 2022
Innovation in BCMA CAR-T therapy: Building beyond the Model T
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1070353
- 10,559 views
- 11 citations
Review
Published on 22 Oct 2024
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1433774
- 9,045 views
- 13 citations
Review
Published on 09 Aug 2023
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
in NK and Innate Lymphoid Cell Biology
Frontiers in Immunology
doi 10.3389/fimmu.2023.1207276
- 28,928 views
- 51 citations
Review
Published on 15 Feb 2022
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2022.825979
- 15,675 views
- 32 citations
Case Report
Published on 25 Feb 2021
Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2021.552429
- 5,833 views
- 11 citations
Review
Published on 10 Apr 2024
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1394048
- 12,286 views
- 13 citations
Case Report
Published on 21 Sep 2022
Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.901266
- 7,564 views
- 15 citations
Case Report
Published on 26 May 2025
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1567403
- 5,424 views
- 1 citation
Review
Published on 18 Oct 2022
Bispecific antibodies in multiple myeloma treatment: A journey in progress
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1032775
- 30,833 views
- 49 citations